Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura

被引：0
|
作者：
Reti, Marienn [1 ]
Sinkovits, Gyorgy [2 ]
Varkonyi, Andrea [1 ]
Kiraly, Agnes [1 ]
Farkas, Zita [1 ]
Bogsch, Luca [1 ]
Icleanu, Andreea-Adela [2 ]
Masszi, Tamas [2 ]
Valyi-Nagy, Istvan [1 ]
Prohaszka, Zoltan [2 ]
Remenyi, Peter Pal [1 ]
机构：
[1] Cent Hosp Southern Pest, Natl Inst Hematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, Budapest, Hungary
[2] Semmelweis Univ, Eotvos Lorand Res Network, Off Supported Res Grp, Dept Internal Med & Hematol, Budapest, Hungary
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
    Gavriilaki, Eleni
    Nikolousis, Emmanuel
    Koravou, Eudoxia-Evaggelia
    Dimou-Besikli, Sotiria
    Kartsios, Charalampos
    Papakonstantinou, Anna
    Mpanti, Anastasia
    Pontikoglou, Charalampos
    Kalpadaki, Christina
    Bitsani, Aikaterini
    Tassi, Ilianna
    Touloumenidou, Tasoula
    Chatziconstantinou, Thomas
    Papathanasiou, Maria
    Syrigou, Antonia
    Ztriva, Eleutheria
    Kaiafa, Georgia
    Mandala, Evdokia
    Mellios, Zois
    Karakasis, Dimitrios
    Kourakli, Alexandra
    Symeonidis, Argiris
    Kapsali, Eleni
    Papadaki, Helen H.
    Lalayanni, Chrysavgi
    Sakellari, Ioanna
    FRONTIERS IN MEDICINE, 2023, 10
  • [22] Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience
    Taylor, Alice
    Keogh, Louisa
    Dickens, Emmy
    Dutt, Tina
    Grainger, John
    Gregory, Rennick
    Mapplebeck, Claire
    Richards, Michael
    Stokley, Simone
    Salta, Styliani
    Taylor, Thomas
    Scully, Marie
    BLOOD ADVANCES, 2024, 8 (17) : 4563 - 4567
  • [23] Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?
    Elverdi, Tugrul
    Ozer Cerme, Melis Dila
    Aydin, Tahacan
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (10) : 1183 - 1188
  • [24] More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
    Picod, Adrien
    Benhamou, Ygal
    Bouzid, Raida
    Veyradier, Agnes
    Coppo, Paul
    BLOOD ADVANCES, 2023, 7 (12) : 2678 - 2680
  • [25] Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
    Sukumar, Senthil
    George, James N.
    Cataland, Spero R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : E76 - E77
  • [26] Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
    Hanlon, Ashley
    Metjian, Ara
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [27] Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
    Goshua, George
    Sinha, Pranay
    Hendrickson, Jeanne E.
    Tormey, Christopher A.
    Bendapudi, Pavan
    Lee, Alfred Ian
    BLOOD, 2020, 136
  • [28] Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
    Reid, Justin H.
    Durant, Karin M.
    Chen, Sheh-Li
    Perissinotti, Anthony J.
    King, Richard
    Khoriaty, Rami
    Marini, Bernard L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1695 - 1702
  • [29] Caplacizumab for the Treatment of acquired thrombotic thrombocytopenic Purpura (aTTP)
    Oezcan, F.
    NEPHROLOGE, 2019, 14 (06): : 470 - 472
  • [30] Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura
    Bhoopalan, Senthil Velan
    Hankins, Jane
    George, James
    Ryder, Alex
    Onder, Ali Mirza
    Puri, Latika
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
12345